ALDH1A1-overexpressing cells are differentiated cells but not cancer stem or progenitor cells in human hepatocellular carcinoma

Kaori Tanaka; Hiroyuki Tomita; Kenji Hisamatsu; Noriyuki Nakashima; Yuichiro Hatano; Yoshiyuki Sasaki; Shinji Osada; Takuji Tanaka; Tatsuhiko Miyazaki; Kazuhiro Yoshida; Akira Hara

doi:10.18632/oncotarget.4406

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers: Pathology:

ALDH1A1-overexpressing cells are differentiated cells but not cancer stem or progenitor cells in human hepatocellular carcinoma

Kaori Tanaka _, Hiroyuki Tomita, Kenji Hisamatsu, Noriyuki Nakashima, Yuichiro Hatano, Yoshiyuki Sasaki, Shinji Osada, Takuji Tanaka, Tatsuhiko Miyazaki, Kazuhiro Yoshida and Akira Hara

PDF | HTML | How to cite

Oncotarget. 2015; 6:24722-24732. https://doi.org/10.18632/oncotarget.4406

Metrics: PDF 2412 views | HTML 2399 views | ?

Abstract

Kaori Tanaka1,2, Hiroyuki Tomita1, Kenji Hisamatsu1, Takayuki Nakashima1, Yuichiro Hatano1, Yoshiyuki Sasaki2, Shinji Osada3, Takuji Tanaka4, Tatsuhiko Miyazaki5, Kazuhiro Yoshida2, Akira Hara1

1Department of Tumor Pathology, Gifu University Graduate School of Medicine, Gifu, Japan

2Department of Surgical Oncology, Gifu University Graduate School of Medicine, Gifu, Japan

3Department of Multidisciplinary Therapy for Hepato-Biliary-Pancreatic Cancer, Gifu University Graduate School of Medicine, Gifu, Japan

4Division of Pathology, Gifu Municipal Hospital, Gifu, Japan

5Division of Pathology, Gifu University Hospital, Gifu, Japan

Correspondence to:

Hiroyuki Tomita, e-mail: [email protected]

Keywords: ALDH1A1, hepatocellular carcinoma, prognosis, cancer stem cell marker

Received: May 28, 2015 Accepted: June 08, 2015 Published: June 22, 2015

ABSTRACT

Aldehyde dehydrogenase 1A1 (ALDH1A1) is considered to be a cancer stem cell marker in several human malignancies. However, the role of ALDH1A1 in hepatocellular carcinoma (HCC) has not been well elucidated. In this study, we investigated the relationship between ALDH1A1 and clinicopathological findings and examined whether ALDH1A1 deserves to be a cancer stem cell marker in HCC. Sixty HCC samples obtained from surgical resection were collected for immunohistochemical (IHC) staining. Of these 60 samples, 47 samples of HCC tumorous and non-tumorous tissues were evaluated with qRT-PCR. There was no significant difference in the ALDH1A1-mRNA level between tumorous and non-tumorous tissues. Tumorous ALDH1A1-mRNA level had no relationship with the clinicopathological features. Immunoreactivity of ALDH1A1 was classified into two groups based on the percentage of ALDH1A1-overexpressing cells. The ALDH1A1-high group was significantly associated with low serum levels of α-fetoprotein, small tumor diameter, very little lymphovascular invasion, more differentiated pathology and good stage. The ALDH1A1-high group showed more favorable prognosis for recurrence-free survival. In double-staining IHC, ALDH1A1 was not co-expressed with BMI1, EpCAM, CD13, CD24, CD90 and CD133, which reported as cancer stem cell markers in HCC. In conclusion, ALDH1A1-overexpressing cells could appear to be differentiated cells rather than cancer stem cells in HCC.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 4406

Publication Alerts

Research Papers: Pathology:

ALDH1A1-overexpressing cells are differentiated cells but not cancer stem or progenitor cells in human hepatocellular carcinoma

Abstract